Hint mode is switched on Switch off
For swift navigation between sections

Cypherpunk Technologies
LEI 549300T31SMMJ2DDLI13

PDF download

Choose all Reset all
Download Cancel
Organization name
Cypherpunk Technologies Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.

Awards

News

21/05/2026 Cypherpunk Technologies: Other Information
07/04/2026 Cypherpunk Technologies: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
16/03/2026 Cypherpunk Technologies: Results Of Operations And Financial Condition, Financial Statements And Exhibits
22/01/2026 Cypherpunk Adds Arjun Khemani as Strategic Advisor
30/12/2025 Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC
All organization news

Documentation

IFRS/US GAAP reports

2025
I q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300T31SMMJ2DDLI13
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001509745
  • EIN
    27-4412575
Registration is required to get access.